^
Association details:
| Biomarker: | ER Y537N |
|---|---|
| Cancer: | Ovarian Serous Adenocarcinoma |
| Drug: | fulvestrant (Selective estrogen receptor degrader) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Assessment of activating estrogen receptor 1 (ESR1) mutations in gynecologic malignancies.
Published date:
05/16/2018
Excerpt:
LGSOC patient had a mutESR1 Y537N at diagnosis and has attained prolonged clinical benefit ( > 4 years) with fulvestrant.
DOI:
10.1200/JCO.2018.36.15_suppl.5590
